ATS 2019 Virtual Final Program

P699 STIFLE: An Exploratory Longitudinal Study to Characterize Daily Changes and Relationships in Airway Inflammation, Symptoms, Lung Function, and Reliever Use in Adult Asthma Patients/ T. Harrison, G. Whelan, M. Fagerås, A. Rutgersson, L. Belton, S. Siddiqui, P. Gustafson, Nottingham, United Kingdom, p.A1308 P700 Switching and Combining Biologics in Severe Asthma: Experience from a Large Academic Teaching Center/ L. Eggert, R.S. Chinthrajah, Stanford, CA, p.A1309 P701 Single Center Real World Experience with Mepolizumab for the Treatment of Severe Persistent Eosinophilic Asthma/ E.J. Pennington, M.A. Aronica, M. Boyle, S.C. Erzurum, S.B. Khatri, L. Peterson, S.A.A. Comhair, Cleveland, OH, p.A1310 P702 The Pharmacokinetics and Relative Bioavailability of Mepolizumab 100 mg Liquid Formulation Administered Subcutaneously to Healthy Participants: A Randomized Trial/ S. Shabbir, I. Pouliquen, J.H. Bentley, E.S. Bradford, M.C. Kaisermann, M. Albayaty, Stevenage, United Kingdom, p.A1311 P703 The Clinical Effectiveness and Safety of Benralizumab for Japanese Patients with Severe Asthma/ M. Iikura, A. Tsukada, J. Hirashima, M. Hojo, S. Izumi, H. Sugiyama, Tokyo, Japan, p.A1312 P704 The Fevipiprant Phase IIIb Systemic Corticosteroid Avoidance Study: SHIELD/ K.F. Rabe, A. Bourdin, R. Buhl, W.W. Busse, J. Strigkas, C.B. Pisal, S. Hiltl, C. Mailaender, S. Fucile, P. Altman, Grosshansdorf, Germany, p.A1313 P705 Long-Term Safety of Fevipiprant (QAW039) in Patients with Asthma, Inadequately Controlled on Standard-of-Care Therapy: Design of The Phase III SPIRIT Trial/ E.M. Kerwin, M. Kato, J.F. Maspero, J.M. Felser, B. Boone, M. Smolen, S. Wang, B.A. Knorr, Medford, OR, p.A1314 Facilitator : S.E. Wenzel, MD, ATSF, Pittsburgh, PA P706 Design of a Phase 2b Dose Finding Study of AZD7594, an Inhaled Non-Steroidal, Selective Glucocorticoid Receptor Modulator, for the Treatment of Asthma/ G.L. Chupp, M.N. Brown, K.M. Beeh, U. Wahlby-Hamren, A.-K. Ekelund, E. Barkstedt, H. Forsman, E. Björnsson, A. Jauhiainen, J. Steele, I. Psallidas, New Haven, CT, p.A1315 P707 Pharmacokinetics, Safety and Tolerability of Single Doses of Budesonide Delivered by AKITA ® JET and Conventional Nebulizer in Healthy Adult Volunteers and Patients with Asthma/ G. Burgess, M. Huyghe, B. Mullinger, S. Snape, Chippenham, United Kingdom, p.A1316 P708 Inhalation of Budesonide Compound Solution with Procaterol Shortens Hospitalization Due to Asthma Attacks/ K. Ito, Y. Kanemitsu, Y. Inoue, S. Yamamoto, H. Nishiyama, R. Kurokawa, N. Takeda, K. Fukumitsu, S. Fukuda, H. Ohkubo, M. Takemura, K. Maeno, Y. Ito, A. Niimi, Nagoya, Japan, p.A1317 P709 Reduced Prescriptions of Salbutamol in Patients Initiated on Fluticasone Furoate/Vilanterol (FF/VI) Compared with Continuing Usual Care (UC) in the Asthma Salford Lung Study (SLS Asthma)/ H. Svedsater, L. Jacques, D. Powell, J. Lay-Flurrie, S. Collier, Brentford, United Kingdom, p.A1318 P710 A Dose Ranging Study of Albuterol Sulfate MDI in Co-Suspension Delivery Technology (AS MDI; PT007) in Patients with Asthma/ C. Cappelletti, A. Maes, K. Rossman, E.M. Kerwin, C. Reisner, Durham, NC, p.A1319 P711 Oral Corticosteroid Tapering During Benralizumab Treatment of Severe, Uncontrolled Eosinophilic Asthma: PONENTE Phase IIIb Clinical Trial/ A. Menzies-Gow, J. Corren, E. Bel, J. Maspero, L. Heaney, M. Gurnell, P. Wessman, U. Martin, S. Siddiqui, E. Garcia Gil, London, United Kingdom, p.A1320 P712 Chronic Use of Oral Corticosteroids in Severe Asthmatics in the Belgian Severe Asthma Registry (BSAR)/ S. Vanwynsberghe, F. Schleich, R. Louis, O. Vandenplas, C. Pilette, R. Peche, G. Joos, S. Dobbelaere, D. Schuermans, S. Hanon, A. Michils, G. Brusselle, Ghent, Belgium, p.A1321 P713 Evaluating the Effectiveness of a Commercial Portable Air Purifier in Asthma/ T. Jinta, W. Fruie, Y. Otani, C. Tani, Y. Takemoto, M. Waku, T. Miyoshi, F. Koike, T. Kubota, Y. Miyazaki, M. Akaza, Y. Sumi, Tokyo, Japan, p.A1322 P714 Relationship Between Alveolar No and Aerobic Capacity or Physical Activity in Asthma/ T. Hirano, K. Matsuda, S. Uehara, K. Hamada, R. Suetake, K. Oishi, Y. Yamaji, M. Asami, N. Edakuni, K. Matsunaga, Ube, Japan, p.A1323 P715 The Effectiveness of Anti-Inflammatory Therapy in Severe Asthma in Patients with Cold Airway Hyperresponsiveness/ J.M. Perelman, A.B. Pirogov, A.G. Prikhodko, D.A. Gassan, V.P. Kolosov, Blagoveshchensk, Russian Federation, p.A1324 P716 The Characteristics of Patients with Exercise-Induced Asthma in the Japanese Severe Asthma Cohort/ T. Mochimaru, S. Ueda, J. Miyata, M. Matsusaka, T. Tanosaki, S. Okuzumi, M. Kuwae, R. Watanabe, M. Nishiura, K. Masaki, Y. Suzuki, K. Asano, K. Fukunaga, Tokyo, Japan, p.A1325 Facilitator : J.W. Upham, MD, PhD, Woolloongabba, Australia P717 Concordance of Changes in Exhaled Nitric Oxide, ACQ7, Asthma Symptoms and Lung Function/ P.E. Silkoff, R. Leard, V. Balasubramanyam, M. Sarno, S. Ssenyange, Philadelphia, PA, p.A1326 P718 pH Measurements in Induced Sputum of Asthmatics and Healthy Volunteers: Association with Markers of Airways Inflammation/ N.E. Alexis, D. Goodfriend, H. Wells, C. Ways, Chapel Hill, NC, p.A1327 P719 Asthma/ Q. Zhang, X. Fu, L. Zhu, W. Gu, J. Kang, S. Chao, Z. Qiu, H. Shen, C. Wang, L. Zhao, Y. Chen, S. Lim, K.F. Chung, C. Xiao, N. Zhong, Guangzhou, China, p.A1328 P720 Asthmatic and Chronic Obstructive Pulmonary Disease Patients Who Participate in Clinical Trials Have Better Inhaler Technique/ T.H. Ahmed Zobair, M. Leite, R. Van Zyl Smit, Cape Town, South Africa, p.A1329 P721 The Effects of Bronchial Thermoplasty Procedure on Patient’s Asthma Control Test and Anxiety Level/ A. Alismail, K. Sutzko, A. Yanez, R. Ramirez, L. Tan, Loma Linda, CA, p.A1330 ATS 2019 • Dallas, TX SUNDAY • MAY 19 47 SUNDAY MORNING